444 related articles for article (PubMed ID: 31610249)
1. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
Tharmalingam H; Tsang Y; Choudhury A; Alonzi R; Wylie J; Ahmed I; Henry A; Heath C; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):525-533. PubMed ID: 31610249
[TBL] [Abstract][Full Text] [Related]
2. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
3. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Roach M; Moughan J; Lawton CAF; Dicker AP; Zeitzer KL; Gore EM; Kwok Y; Seider MJ; Hsu IC; Hartford AC; Horwitz EM; Yamoah K; Jones CU; Michalski JM; Lee WR; Pisansky TM; Rabinovitch R; Rotman M; Pryzant RM; Kim HE; Thomas CR; Shipley WU; Sandler HM
Lancet Oncol; 2018 Nov; 19(11):1504-1515. PubMed ID: 30316827
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
7. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
[TBL] [Abstract][Full Text] [Related]
8. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and Biochemical Outcomes of Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial.
Qi X; Li HZ; Gao XS; Qin SB; Zhang M; Li XM; Li XY; Ma MW; Bai Y; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):282-290. PubMed ID: 31669564
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
[TBL] [Abstract][Full Text] [Related]
12. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
13. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
14. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
16. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
[TBL] [Abstract][Full Text] [Related]
17. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
18. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.
Hauswald H; Kamrava MR; Fallon JM; Wang PC; Park SJ; Van T; Borja L; Steinberg ML; Demanes DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):667-74. PubMed ID: 26443877
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
20. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]